4.6 Article

CD5 Promotes IL-10 Production in Chronic Lymphocytic Leukemia B Cells through STAT3 and NFAT2 Activation

Journal

JOURNAL OF IMMUNOLOGY
Volume 186, Issue 8, Pages 4835-4844

Publisher

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1003050

Keywords

-

Categories

Funding

  1. Ligue contre le Cancer
  2. Conseil Regional de Bretagne
  3. Conseil General du Finistere
  4. Doctoral International Committee of the European University of Brittany

Ask authors/readers for more resources

B lymphocytes from chronic lymphocytic leukemia (CLL) display some CD5 transcripts for CD5 containing the known exon 1 (E1A) and other CD5 transcripts containing the new exon 1 (E1B). These malignant B cells, as well as B cell lines transfected with cDNA for E1A-cd5 or with cDNA for E1B-cd5 produce IL-10, raising the possibility that CD5 participates in the secretion of IL-10. We identified transcription factors involved in this production in CD5(+) B lymphocytes from CLL patients and in E1A-cd5-transfected or E1B-cd5-transfected Jok cells. STAT3 is activated via phosphorylation of serine 727 but also NFAT2 through its translocation into the nucleus. Chromatin immunoprecipitation experiments confirmed the role of STAT3 and allowed the discovery of a role for NFAT2 in IL-10 production. Both transcription factors bind not only to the enhancer of the Il-10 gene but also to the promoter of the Il-5 and Il-13 genes. Furthermore, transfection of B cell lines with E1A-cd5 or E1B-cd5 established that activation of STAT3 and NFAT2 is regulated by CD5. The same holds true for the production of IL-10, IL-5, and IL-13 and the expression of the receptors for these cytokines. This interpretation was confirmed by two experiments. In the first, downregulation of CD5 by small interfering RNAs lowered the production of IL-10. In the second experiment, transfection of the GFP-NFAT2 gene into B lymphocytes induced nuclear translocation of NFAT2 in CD5(+) but not in CD5(-) B cells. Thus, CD5 expression is associated with NFAT2 activity (and mildly STAT3 activity), indicating that CD5 controls IL-10 secretion. The Journal of Immunology, 2011, 186: 4835-4844.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Cell Biology

Identification of altered cell signaling pathways using proteomic profiling in stable and progressive chronic lymphocytic leukemia

Cristina Bagacean, Cristina Adela Iuga, Anne Bordron, Adrian Tempescul, Ioana-Ecaterina Pralea, Delphine Bernard, Melanie Cornen, Tiffany Bergot, Christelle Le Dantec, Wesley Brooks, Hussam Saad, Jean-Christophe Ianotto, Jacques-Olivier Pers, Mihnea Zdrenghea, Christian Berthou, Yves Renaudineau

Summary: Chronic lymphocytic leukemia (CLL) is characterized by significant biologic and clinical heterogeneity. This study investigated the proteomic profiles of CLL B-cells, showing differences between stable and progressive disease groups at an early stage, with RNA splicing dysregulation underlying CLL evolution and impacting B-cell survival and migration.

JOURNAL OF LEUKOCYTE BIOLOGY (2022)

Article Immunology

Lupus band test can be used in combination with anti-chromatin antibodies and complement analysis to predict transition from cutaneous to systemic lupus

Caroline Carle, Francoise Fortenfant, Marie Tauber, Emilie Tournier, Carle Paul, Chloe Bost, Yves Renaudineau

Summary: The lupus band test is debated for its ability to distinguish between cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE), and its association with antinuclear antibodies (ANA) and complement reduction. Certain clinical, histopathologic, and serological parameters can effectively differentiate lupus from other skin disorders and distinguish between SLE and CLE.

CLINICAL IMMUNOLOGY (2022)

Article Respiratory System

Safety and pharmacokinetics of Roscovitine (Seliciclib) in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa, a randomized, placebo-controlled study

Laurent Meijer, Genevieve Hery-Arnaud, Cyril Leven, Emmanuel Nowak, Sophie Hillion, Yves Renaudineau, Isabelle Durieu, Raphael Chiron, Anne Prevotat, Isabelle Fajac, Dominique Hubert, Marlene Murris-Espin, Sandrine Huge, Isabelle Danner-Boucher, Bruno Ravoninjatovo, Sylvie Leroy, Julie Macey, Thierry Urban, Gilles Rault, Dominique Mottier, Rozenn Le Berre

Summary: A study was conducted to evaluate the safety and effects of roscovitine in patients with Cushing disease. The results showed that roscovitine was relatively safe and well-tolerated, but did not show significant efficacy in treating the disease. The variability in pharmacokinetics of roscovitine may have contributed to the lack of effectiveness.

JOURNAL OF CYSTIC FIBROSIS (2022)

Article Gastroenterology & Hepatology

Altered DNA methylation pattern characterizes the peripheral immune cells of patients with autoimmune hepatitis

Kalliopi Zachou, Pinelopi Arvaniti, Aggeliki Lyberopoulou, Eirini Sevdali, Matthaios Speletas, Maria Ioannou, George K. Koukoulis, Yves Renaudineau, George N. Dalekos

Summary: This study investigated the alterations of DNA methylation in peripheral lymphocytes of patients with autoimmune hepatitis (AIH) at diagnosis and remission. The results showed abnormal expressions of TET1 and DNMT3A in AIH patients' lymphocytes, which were associated with disease activity and may affect immunological pathways.

LIVER INTERNATIONAL (2022)

Article Oncology

Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial

Julia Katharina Schwarze, Soizic Garaud, Yanina J. L. Jansen, Gil Awada, Valerie Vandersleyen, Jens Tijtgat, Alexandre de Wind, Paulus Kristanto, Teofila Seremet, Karen Willard-Gallo, Bart Neyns

Summary: Low-dose regimens of PD-1 immune checkpoint inhibitors may serve as effective and cost-efficient alternatives to standard dosing in melanoma patients. Immunohistochemical tumor profiling shows promise as a potential biomarker.

CANCERS (2022)

Article Immunology

Glucocorticoid use as a cause of non-cellular immune response to SARS-Cov2 Spike in patients with immune system diseases

Yves Renaudineau, Laurent Sailler, Florence Abravanel, Jacques Izopet, Adrien Delourme, Damien Biotti, Jonathan Ciron, Emmanuel Treiner, Nicolas Congy-Jolivet, Chloe Bost, Antoine Blancher

Summary: Disease modifying therapies can compromise the immune response to the SARS-Cov2 virus and its vaccine in patients with immune system diseases. A retrospective study evaluated the impact of COVID-19 immunization on immune system disease patients and found that certain treatments and patient characteristics were associated with negative cellular and humoral responses.

JOURNAL OF AUTOIMMUNITY (2022)

Article Immunology

JAK inhibition for CD3- CD4+ lymphocytic-variant hypereosinophilic syndrome

Stanislas Faguer, Matthieu Groh, Francois Vergez, Mathilde Hunault-Berger, Nicolas Duployez, Yves Renaudineau, Carle Paul, Guillaume Lefevre, Jean-Emmanuel Kahn

Summary: Alternatives are required for CD3(-) CD4(+) lymphocytic-variant hypereosinophilic syndrome patients who do not respond well to high-dose steroids or conventional therapies. This study reports successful treatment of five L-HES patients with cutaneous involvement and persistent eosinophilia by using JAK inhibitors. Complete clinical remission was achieved in all patients within three months, and adverse events were not observed during follow-up. Prospective clinical trials are needed to further investigate the use of JAK inhibitors in L-HES.

CLINICAL IMMUNOLOGY (2023)

Review Biochemistry & Molecular Biology

Characteristics of the (Auto)Reactive T Cells in Rheumatoid Arthritis According to the Immune Epitope Database

Caroline Carle, Yannick Degboe, Adeline Ruyssen-Witrand, Marina I. Arleevskaya, Cyril Clavel, Yves Renaudineau

Summary: T cells play a crucial role in the development of rheumatoid arthritis (RA). A comprehensive review based on the analysis of the Immune Epitope Database (IEDB) was conducted to better understand the contribution of T cells to RA. It was found that an immune CD8+ T cell senescence response is present in RA and inflammatory diseases, driven by viral antigens and self-apoptotic peptides. Additionally, pro-inflammatory CD4+ T cells in RA are selected by MHC class II and immunodominant peptides derived from molecular chaperones, host peptides, and bacterial cross-reactive peptides.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Biochemistry & Molecular Biology

Lupus Nephritis Risk Factors and Biomarkers: An Update

Yves Renaudineau, Wesley Brooks, Julie Belliere

Summary: Lupus nephritis is the most severe organ manifestation of systemic lupus erythematosus. Efforts have been made to characterize the different steps of the disease and develop biomarkers for early diagnosis, disease monitoring, and preventing complications.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Immunology

Immunological and translational key challenges in systemic lupus erythematosus: A symposium update

Yves Renaudineau, Sylviane Muller, Christian M. Hedrich, Dominique Chauveau, Julie Belliere, Sebastien De Almeida, Jan Damoiseaux, Marc Scherlinger, Jean Charles Guery, Laurent Sailler, Chloe Bost

Summary: The first LBMR-Tim symposium, held on December 16, 2022 in Toulouse, France, focused on addressing challenging questions in systemic lupus erythematosus (SLE). The symposium discussed the role of genes, sex, TLR7, and platelets in SLE pathophysiology, as well as the contributions of autoantibodies, urinary proteins, and thrombocytopenia at the time of diagnosis and during follow-up. It also explored topics such as neuropsychiatric involvement, vaccine response in the COVID-19 era, lupus nephritis management, and therapeutic perspectives for patients with lupus nephritis.

JOURNAL OF TRANSLATIONAL AUTOIMMUNITY (2023)

Article Immunology

Glucocorticoids selectively affect the memory T cell response to SARS-Cov2 spike in vaccinated and post-infected patients with systemic lupus erythematosus

Yves Renaudineau, Chloe Bost, Florence Abravanel, Jacques Izopet, Antoine Blancher, Nicolas Congy, Emmanuel Treiner, Laurent Sailler

Summary: The immune response to vaccines and pathogens in patients with systemic lupus erythematosus (SLE) is not well understood. A retrospective study of 47 SLE patients vaccinated against COVID-19 showed that SLE patients had reduced post-vaccine response against the Spike protein compared to controls. This reduction was observed in both memory T-cell response and IgG anti-Spike antibody response. The defective response was associated with low serum albumin levels, the use of glucocorticoids, and lower levels of specific antibodies.

JOURNAL OF TRANSLATIONAL AUTOIMMUNITY (2023)

Article Immunology

Cerebrospinal fluid YKL-40 level evolution is associated with autoimmune encephalitis remission

Guillaume Dorcet, Marie Benaiteau, Jeremie Pariente, Fabienne Ory-Magne, Emmanuel Cheuret, Marie Rafiq, Wesley Brooks, Benedicte Puissant-Lubrano, Francoise Fortenfant, Yves Renaudineau, Chloe Bost

Summary: This study aimed to explore the correlation between several biomarkers and the clinical course of autoimmune encephalitis (AIE). The results showed that the decrease in YKL-40 and MMP-9A at the protein level was associated with AIE remission, and the decrease in NfL and NfH levels in the serum was also associated with AIE remission. The study suggests that YKL-40 can be used as a biomarker to evaluate disease activity and therapeutic response in AIE.

CLINICAL & TRANSLATIONAL IMMUNOLOGY (2023)

Article Immunology

Low performance of interferon gamma release assay Quantiferon-TB gold coupled or not with Pst1/3/lipoglycan humoral detection to predict Mycobacterium tuberculosis complex disease in a low-burden area

Silvia Martinez-Rivera, Helene Guet-Revillet, Fabrice Herin, Guillaume Martin-Blondel, Marcel Miedouge, Laura Billon, Emmanuel Treiner, Yves Renaudineau

Summary: The study evaluated the use of QTF-TB and mycobacterial infection testing to differentiate MTC exposure from active disease. QTF-TB had limited ability to distinguish between LTBI and active MTC disease, but a cut-off value of 4.4 IFN-gamma IU/mL showed the best diagnostic performance for MTC detection. Antibodies were detected in active MTC disease cases using the humoral assay, but not in LTBI or negative QTF-TB cases.

TUBERCULOSIS (2023)

Review Rheumatology

Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases

Alice Tison, Soizic Garaud, Laurent Chiche, Divi Cornec, Marie Kostine

Summary: Immune-checkpoint inhibitors have changed the management of advanced cancers, but can also cause immune-related adverse events. Evidence is accumulating regarding the use of these inhibitors in patients with pre-existing autoimmune disease, suggesting acceptable safety but a risk of disease flare or other adverse events. Proper management of immunosuppressive drugs is important to balance autoimmunity protection and tumor response, and there is emerging research on the potential synergy of TNF or IL-6 inhibitors with immune-checkpoint inhibitors.

NATURE REVIEWS RHEUMATOLOGY (2022)

Article Immunology

SARS-Cov2 acute and post-active infection in the context of autoimmune and chronic inflammatory diseases

Regina Larionova, K. Byvaltsev, Olga Kravtsova, Elena Takha, Sergei Petrov, Gevorg Kazarian, Anna Valeeva, Eduard Shuralev, Malik Mukminov, Yves Renaudineau, Marina Arleevskaya

Summary: The clinical and immunological spectrum of acute and post-active COVID-19 syndrome overlaps with criteria used to characterize autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The immune response after SARS-Cov2 infection is altered with delayed production of IFN-I and activation of NF-kappa B and inflammasome pathways. An alternative immune response against SARS-Cov2 occurs in the lungs and digestive tissues, leading to breakdown of tolerance and the emergence of autoantibodies. The risk of severe COVID-19 in SLE and RA patients is similar to the general population, unless they have pre-existing neutralizing autoantibodies against IFN-I. Discontinuation of treatment increases the risk of flares. There have been a few case reports of individuals developing SLE or RA following COVID-19 infection/vaccination. Overall, the SARS-Cov2 pandemic provides a unique opportunity to study the dangerous interplay between immune response and autoimmunity, and understand the role of infection as a triggering factor in autoimmune and chronic inflammatory disease development.

JOURNAL OF TRANSLATIONAL AUTOIMMUNITY (2022)

No Data Available